HUE057769T2 - Eljárás rivaroxaban kristályosítására - Google Patents

Eljárás rivaroxaban kristályosítására

Info

Publication number
HUE057769T2
HUE057769T2 HUE10740170A HUE10740170A HUE057769T2 HU E057769 T2 HUE057769 T2 HU E057769T2 HU E10740170 A HUE10740170 A HU E10740170A HU E10740170 A HUE10740170 A HU E10740170A HU E057769 T2 HUE057769 T2 HU E057769T2
Authority
HU
Hungary
Prior art keywords
rivaroxaban
crystallization
processes
Prior art date
Application number
HUE10740170A
Other languages
English (en)
Inventor
Silvo Zupancic
Anica Pecavar
Original Assignee
Krka D D Novo Mesto
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Krka D D Novo Mesto filed Critical Krka D D Novo Mesto
Publication of HUE057769T2 publication Critical patent/HUE057769T2/hu

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
HUE10740170A 2009-07-31 2010-07-30 Eljárás rivaroxaban kristályosítására HUE057769T2 (hu)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SI200900218 2009-07-31

Publications (1)

Publication Number Publication Date
HUE057769T2 true HUE057769T2 (hu) 2022-06-28

Family

ID=42831508

Family Applications (1)

Application Number Title Priority Date Filing Date
HUE10740170A HUE057769T2 (hu) 2009-07-31 2010-07-30 Eljárás rivaroxaban kristályosítására

Country Status (7)

Country Link
EP (1) EP2459555B1 (hu)
EA (1) EA031064B2 (hu)
ES (1) ES2905760T3 (hu)
HU (1) HUE057769T2 (hu)
PL (1) PL2459555T3 (hu)
SI (1) SI2459555T1 (hu)
WO (1) WO2011012321A1 (hu)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA114601C2 (uk) * 2011-05-06 2017-07-10 Егіш Дьйодьсердьяр Нільваношан Мюкеде Ресвеньтаршашаг Спосіб одержання ривароксабану та проміжних сполук, які одержано в даному способі
CN102827154B (zh) * 2011-06-14 2015-04-22 上海科胜药物研发有限公司 一种合成利伐沙班中间体4-{4-[(5s)-5-(氨基甲基)-2-氧代-1,3-恶唑烷-3-基]苯基}吗啉-3-酮的方法
CN103012388B (zh) * 2011-09-20 2016-01-20 联化科技(上海)有限公司 一种利伐沙班及其中间体的制备方法,以及中间体化合物
EP2573084A1 (en) * 2011-09-22 2013-03-27 Enantia, S.L. Novel crystalline forms of rivaroxaban and processes for their preparation
AU2012378913B2 (en) 2012-05-02 2017-04-13 Symed Labs Limited Improved process for preparing rivaroxaban using novel intermediates
WO2014020458A1 (en) * 2012-08-01 2014-02-06 Alembic Pharmaceuticals Limited Improved process for preparation of rivaroxaban
HUE037188T2 (hu) 2012-12-21 2018-08-28 Farma Grs D O O Eljárás rivaroxaban elõállítására
US9394292B2 (en) 2012-12-26 2016-07-19 Wanbury Ltd. Rivaroxaban intermediate and preparation thereof
EP2897619A4 (en) 2012-12-26 2016-08-17 Wanbury Ltd ALDEHYDE DERIVATIVE FROM SUBSTITUTED OXAZOLIDINONES
IN2013MU01113A (hu) * 2013-03-25 2015-06-19 Glenmark Generics Ltd
CN104109158A (zh) * 2013-04-16 2014-10-22 上海医药工业研究院 一种纯化利伐沙班的方法
CN104650058A (zh) * 2013-11-23 2015-05-27 天津市汉康医药生物技术有限公司 利伐沙班一水合物化合物
IN2014MU00072A (hu) 2014-01-08 2015-08-21 Wockhardt Ltd
IN2014CH00290A (hu) 2014-01-23 2015-08-14 Symed Labs Ltd
WO2015198259A1 (en) 2014-06-26 2015-12-30 Erregierre S.P.A. Process for the synthesis of rivaroxaban and intermediate for the production thereof
CN104211693B (zh) * 2014-08-07 2017-02-22 成都百裕制药股份有限公司 一种利伐沙班晶型及其制备方法与用途
CN105503849B (zh) * 2014-09-26 2019-10-08 重庆华邦胜凯制药有限公司 一种制备小粒度利伐沙班原料药的方法
EA034656B1 (ru) * 2014-10-22 2020-03-03 Закляды Фармацеутычне Польфарма С.А Способ получения полиморфа ривароксабана
CN107778303B (zh) * 2016-08-27 2020-03-24 鲁南制药集团股份有限公司 利伐沙班的精制方法
CN108344832B (zh) * 2017-12-28 2021-03-09 江苏悦兴医药技术有限公司 一种主成分与其杂质完全分离的检测方法
CN109142601B (zh) * 2018-10-25 2021-03-12 重庆华邦胜凯制药有限公司 一种分离利伐沙班中间体及其杂质的方法
CN111518092B (zh) * 2019-02-01 2022-12-20 鲁南制药集团股份有限公司 利伐沙班乙酸溶剂合物及其制备方法
CN110003193B (zh) * 2019-04-02 2023-12-05 北京四环制药有限公司 一种制备易于粉碎的利伐沙班及其制备方法
CN111721858B (zh) * 2020-06-03 2022-07-01 杭州华东医药集团新药研究院有限公司 一种测定利伐沙班中基因毒性杂质的方法
GR1010231B (el) * 2021-03-24 2022-05-10 Φαρματεν Α.Β.Ε.Ε., Φαρμακευτικο σκευασμα που περιλαμβανει ριβαροξαμπανη και μεθοδος παρασκευης αυτου
EP4201933A1 (en) 2021-12-23 2023-06-28 Zaklady Farmaceutyczne Polpharma S.A. Crystallisation process for rivaroxaban

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19962924A1 (de) 1999-12-24 2001-07-05 Bayer Ag Substituierte Oxazolidinone und ihre Verwendung
DE10129725A1 (de) 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
DE10300111A1 (de) 2003-01-07 2004-07-15 Bayer Healthcare Ag Verfahren zur Herstellung von 5-Chlor-N-({(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophencarboxamid
DE102004002044A1 (de) 2004-01-15 2005-08-04 Bayer Healthcare Ag Herstellverfahren
CA2624310C (en) 2005-10-04 2014-01-07 Bayer Healthcare Ag Polymorphic form of 5-chloro-n-({5s)-2-oxo-3-[4-(3-oxo-4-morpholinyl)-phenyl]-1,3-oxazolidin-5-yl}-methyl)-2-thiophenecarboxamide
RU2494740C2 (ru) * 2007-12-11 2013-10-10 Байер Интеллектуэль Проперти Гмбх Оксазолидиноны для лечения и/или профилактики расстройств сердечной деятельности
US20100168111A1 (en) 2008-12-31 2010-07-01 Apotex Pharmachem Inc. Polymorphic form of 5 chloro n {[(5s) 2 oxo 3 [4 (3 oxomorpholin 4 yl)phenyl]oxa-zolidin 5 yl]-methyl}thiophene 2 carboxamide
WO2014020458A1 (en) 2012-08-01 2014-02-06 Alembic Pharmaceuticals Limited Improved process for preparation of rivaroxaban

Also Published As

Publication number Publication date
EP2459555A1 (en) 2012-06-06
EA031064B2 (ru) 2020-07-01
ES2905760T3 (es) 2022-04-12
SI2459555T1 (sl) 2022-03-31
PL2459555T3 (pl) 2022-03-28
WO2011012321A1 (en) 2011-02-03
EA031064B1 (ru) 2018-11-30
EA201290074A1 (ru) 2012-07-30
EP2459555B1 (en) 2021-11-03

Similar Documents

Publication Publication Date Title
PL2459555T3 (pl) Sposoby krystalizacji rywaroksabanu
IL283038A (en) Processes for preparing intermediates for protein tyrosine kinase inhibitors
HK1254977A1 (zh) 索非布韋(sofosbuvir)的結晶形式
ZA201600646B (en) Process for beta-lactone production
PT2634191E (pt) Processo para preparar derivados de tienopirimidinadiona
EP2480523A4 (en) PROCESS FOR THE PRODUCTION OF N-ACYLBPHENYLALANINE
EP2439312A4 (en) PROCESS FOR PRODUCING REDUCED GLUTATHION
EP2407461A4 (en) PROCESS FOR PREPARING 1-ALKYL-5-BENZOYL-1H-TETRAZOL DERIVATIVES
IL216942A0 (en) Process for the manufacture of alkenones
ZA201202343B (en) Process for the preparation of lenalidomide
EP2292579A4 (en) PROCESS FOR THE PRODUCTION OF HALOGENATED FLUOROETHERS
EP2400848A4 (en) CRYSTALLIZATION OF PHARMACEUTICAL COMPOUNDS
ZA201109045B (en) Crystalline form of pemirolast
EP2514719A4 (en) PROCESS FOR SYNTHESIS OF AMMONIA
EP2423187A4 (en) PROCESS FOR PRODUCING N-ALCOXYCARBONYL-tert-LEUCINS
EP2491044A4 (en) IMPROVED METHOD FOR THE PREPARATION OF CLOPIODOGREL BISULFATE IN THE CRYSTAL FORM 1
EP2511234A4 (en) PROCESS FOR THE PRODUCTION OF DDR ZEOLITE
EP2514783A4 (en) METHOD FOR PRODUCING AN ORGANOPOLYSILOXAN COMPOUND
EP2423212A4 (en) PROCESS FOR PREPARING A 2-AZAADAMANTAN COMPOUND FROM A BICYCLOCARBAMATE COMPOUND
EP2281780A4 (en) PROCESS FOR PREPARING SILICON
EP2251329A4 (en) PROCESS FOR THE PRODUCTION OF 3-AMINO-2-CHLORO-6-TRIFLUOROMETHYLPYRIDINE
GB0906289D0 (en) Processes for making isoxazoline derivatives
EP2514784A4 (en) PROCESS FOR THE PRODUCTION OF ORGANOPOLYSILOXANE COMPOUND
GB0913427D0 (en) Compounds for treatment of imflammation
EP2514302A4 (en) PROCESS FOR PRODUCING MULTI-PETAL CYCLAMEN